Business Context and Reporting Period
This Form 8-K filing by Matinas Biopharma Holdings, Inc. (Delaware) reports a corporate governance event dated June 14, 2018. The company is classified as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the termination of Dominick M. DiPaolo, who served as the Company's Senior Vice President of Quality and Regulatory Compliance. The termination was effective immediately on June 14, 2018.
Management Commentary and Contingencies
- Severance Arrangement: Mr. DiPaolo is entitled to receive one month of base salary as severance.
- Conditions: Payment is subject to the execution of a separation agreement and a general release.
- Payment Method: Severance will be paid in accordance with the Company's standard payroll practices.
Investor Verification Checklist
- Confirm the execution status of the separation agreement and general release required for severance payment.
- Verify the Company's plan for interim or permanent replacement of the Senior Vice President of Quality and Regulatory Compliance.
- Assess potential impacts on ongoing regulatory compliance activities due to the leadership change.